Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3b Open-label Study of Burosumab in Adults With XLH
2018-000202-37Phase 3Completed
- Sponsor
- Kyowa Kirin
- Start
- Aug 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of burosumab in X-linked hypophosphataemia (XLH) and Hereditary Hypophosphatemic Rickets (XLH), sponsored by Kyowa Kirin. Primary endpoint: Serum phosphate maintenance. Started Aug 2018; status: completed.
02
Drugs
burosumab
03
Conditions
X-linked hypophosphataemia (XLH)Hereditary Hypophosphatemic Rickets (XLH)
Beyond the preview
Go deeper on 2018-000202-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000202-37.